Growth factors and neuropathic pain

Current Pain and Headache Reports

Volumn 15, Issue 3, 2011, Pages 185-192

  Ossipov, Michael H ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Afferent drive; Artemin; GDNF; GFR 3; GFRalpha3; Glial derived neurotrophic factor; Nerve growth factor; Neuropathic pain; Neuropathy; NGF; Wallerian degeneration

Indexed keywords

ANALGESIC AGENT; ANTIPARKINSON AGENT; ARTEMIN; FULRANUMAB; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; LIATERMIN; MEDI 578; N (2 HYDROXYETHYLAMINO) 3 NITRONAPHTHALIMIDE; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR INHIBITOR; PROTEIN TYROSINE KINASE A IMMUNOGLOBULIN G FUSION PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT NERVE GROWTH FACTOR; REGN 475; SAR 164877; TANEZUMAB; UNCLASSIFIED DRUG;

ALLODYNIA; ANOREXIA; BONE PAIN; BRAIN ISCHEMIA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL (TOPIC); CYSTITIS; DEPRESSION; DIABETIC NEUROPATHY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HYPERALGESIA; HYPERESTHESIA; HYPERSENSITIVITY; HYPONATREMIA; INFLAMMATION; INJECTION SITE PAIN; JOINT DEGENERATION; LOW BACK PAIN; MECHANICAL ALLODYNIA; MOLECULAR INTERACTION; MYALGIA; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE GROWTH; NERVE INJURY; NERVE REGENERATION; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPROTECTION; NOCICEPTION; NONHUMAN; OSTEOARTHRITIS; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL NERVE INJURY; POSTOPERATIVE PAIN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPINAL GANGLION; STOMATITIS; WEIGHT REDUCTION;

ANALGESICS; ANIMALS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEURALGIA;

EID: 79955881474     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-011-0183-5     Document Type: Review

References (60)

1. Merskey H. Clarifying definition of neuropathic pain. Pain. 2002;96:408-9.
2. Ossipov MH, Porreca F. Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRx. 2005;2:650-61. (Pubitemid 41393272)
3. Sah DW, Ossipov MH, Porreca F. Neurotrophic factors as novel therapeutics for neuropathic pain. Nat Rev Drug Discov. 2003;2:460-72. (Pubitemid 37361727)
4. Sah DW, Ossipov MH, Rossomando A, et al. New approaches for the treatment of pain: the GDNF family of neurotrophic growth factors. Curr Top Med Chem. 2005;5:577-83. (Pubitemid 41052330)
5. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1-32. This is an excellent review of the role of sensitization in neuropathic pain.
6. Yoon YW, Na HS, Chung JM. Contributions of injured and intact afferents to neuropathic pain in an experimental rat model. Pain. 1996;64:27-36. (Pubitemid 26062244)
7. Eschenfelder S, Habler HJ, Janig W. Dorsal root section elicits signs of neuropathic pain rather than reversing them in rats with L5 spinal nerve injury. Pain. 2000;87:213-9. (Pubitemid 30621453)
8. Wu G, Ringkamp M, Murinson BB, et al. Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J Neurosci. 2002;22:7746-53. (Pubitemid 35386373)
9. Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci. 2007;28:68-74. (Pubitemid 46161837)
10. Wang Y, Chang CF, Morales M, et al. Protective effects of glial cell line-derived neurotrophic factor in ischemic brain injury. Ann NY Acad Sci. 2002;962:423-37. (Pubitemid 34592330)
11. Bjorklund A, Rosenblad C, Winkler C, et al. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis. 1997;4:186-200. (Pubitemid 27465509)
12. Alberch J, Perez-Navarro E, Canals JM. Neuroprotection by neurotrophins and GDNF family members in the excitotoxic model of Huntington's disease. Brain Res Bull. 2002;57:817-22. (Pubitemid 34522157)
13. Zhang WR, Hayashi T, Iwai M, et al. Time dependent amelioration against ischemic brain damage by glial cell line-derived neurotrophic factor after transient middle cerebral artery occlusion in rat. Brain Res. 2001;903:253-6. (Pubitemid 32904631)
14. Fjell J, Cummins TR, Dib-Hajj SD, et al. Differential role of GDNF and NGF in the maintenance of two TTX- resistant sodium channels in adult DRG neurons. Brain Res Mol Brain Res. 1999;67:267-82. (Pubitemid 29193183)
15. Bennett DL. Neurotrophic factors: important regulators of nociceptive function. Neuroscientist. 2001;7:13-7. (Pubitemid 32098819)
16. Bennett DL, Michael GJ, Ramachandran N, et al. A distinct subgroup of small DRG cells express GDNF receptor components and GDNF is protective for these neurons after nerve injury. J Neurosci. 1998;18:3059-72. (Pubitemid 28163236)
17. Bennett DL, Boucher TJ, Armanini MP, et al. The glial cell linederived neurotrophic factor family receptor components are differentially regulated within sensory neurons after nerve injury. J Neurosci. 2000;20:427-37. (Pubitemid 30220528)
18. Wang RI, Guo W, Ossipov MH, et al. GDNF Protects a subpopulation of nerve - injured neurons and prevents nerve injury - induced abnormal pain. Society for Neuroscience Abstracts 2002:Program #454.412.
19. Boucher TJ, Okuse K, Bennett DL, et al. Potent analgesic effects of GDNF in neuropathic pain states. Science. 2000;290:124-7.
20. Ramer MS, Priestley JV, McMahon SB. Functional regeneration of sensory axons into the adult spinal cord. Nature. 2000;403:312-6. (Pubitemid 30062387)
21. Barker RA. Parkinson's disease and growth factors - are they the answer? Parkinsonism Relat Disord. 2009;15 Suppl 3:S181-184.
22. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, doubleblind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003;60:69-73. (Pubitemid 36070646)
23. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. 1999;46:419-24. (Pubitemid 29416283)
24. Yasuhara T, Shingo T, Date I. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease. Acta Med Okayama. 2007;61:51-6. (Pubitemid 46798852)
25. Gardell LR, Wang R, Ehrenfels C, et al. Multiple actions of systemic artemin in experimental neuropathy. Nat Med. 2003;9:1383-9. (Pubitemid 37466187)
26. Wang R, King T, Ossipov MH, et al. Persistent restoration of sensory function by immediate or delayed systemic artemin after dorsal root injury. Nat Neurosci. 2008;11:488-96. This article describes how artemin promotes both nerve growth through the DREZ to form functional synapses and growth of myelinated Aβ fibers to dorsal column nuclei.
27. Bolon B, Jing S, Asuncion F, et al. The candidate neuroprotective agent artemin induces autonomic neural dysplasia without preventing peripheral nerve dysfunction. Toxicol Pathol. 2004;32:275-94. (Pubitemid 38691999)
28. Malin SA, Molliver DC, Koerber HR, et al. Glial cell line-derived neurotrophic factor family members sensitize nociceptors in vitro and produce thermal hyperalgesia in vivo. J Neurosci. 2006;26:8588-99. (Pubitemid 44316188)
29. Widenfalk J, Wu W, Hao J, et al. Treatment of transected peripheral nerves with artemin improved motor neuron regeneration, but did not reduce nerve injury-induced pain behaviour. Scand J Plast Reconstr Surg Hand Surg. 2009;43:245-50.
30. Patel TD, Jackman A, Rice FL, et al. Development of sensory neurons in the absence of NGF/TrkA signaling in vivo. Neuron. 2000;25:345-57.
31. Lewin GR, Mendell LM. Nerve growth factor and nociception. Trends Neurosci. 1993;16:353-9. (Pubitemid 23232008)
32. Bennett DL, Averill S, Clary DO, et al. Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons. Eur J Neurosci. 1996;8:2204-8. (Pubitemid 26345794)
33. Averill S, McMahon SB, Clary DO, et al. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur J Neurosci. 1995;7:1484-94.
34. Stucky CL, Shin JB, Lewin GR. Neurotrophin-4: a survival factor for adult sensory neurons. Curr Biol. 2002;12:1401-4. (Pubitemid 34915542)
35. Kawamoto K, Matsuda H. Nerve growth factor and wound healing. Prog Brain Res. 2004;146:369-84. (Pubitemid 37541394)
36. Matsuda H, Koyama H, Sato H, et al. Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. J Exp Med. 1998;187:297-306. (Pubitemid 28080059)
37. McMahon SB, Bennett DL, Bevan S, et al. Inflammatory mediators and modulators of pain. In Wall and Melzack's Textbook of Pain Edited by London: Elsevier; 2005;49-72.
38. Saade NE, Massaad CA, Ochoa-Chaar CI, et al. Upregulation of proinflammatory cytokines and nerve growth factor by intraplantar injection of capsaicin in rats. J Physiol. 2002;545:241-53. (Pubitemid 35396348)
39. Heumann R, Korsching S, Bandtlow C, et al. Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection. J Cell Biol. 1987;104:1623-31. (Pubitemid 17104532)
40. Lee YJ, Zachrisson O, Tonge DA, et al. Upregulation of bradykinin B2 receptor expression by neurotrophic factors and nerve injury in mouse sensory neurons. Mol Cell Neurosci. 2002;19:186-200. (Pubitemid 34211899)
41. Shu X, Mendell LM. Acute sensitization by NGF of the response of small-diameter sensory neurons to capsaicin. J Neurophysiol. 2001;86:2931-8. (Pubitemid 33139060)
42. Bielefeldt K, Ozaki N, Gebhart GF. Experimental ulcers alter voltage-sensitive sodium currents in rat gastric sensory neurons. Gastroenterology. 2002;122:394-405. (Pubitemid 34116991)
43. Campenot RB, MacInnis BL. Retrograde transport of neurotrophins: fact and function. J Neurobiol. 2004;58:217-29. (Pubitemid 38173720)
44. Ji RR, Samad TA, Jin SX, et al. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron. 2002;36:57-68.
45. Malcangio M, Ramer MS, Boucher TJ, et al. Intrathecally injected neurotrophins and the release of substance P from the rat isolated spinal cord. Eur J Neurosci. 2000;12:139-44. (Pubitemid 30068419)
46. Donnerer J, Schuligoi R, Stein C, et al. Upregulation, release and axonal transport of substance P and calcitonin gene-related peptide in adjuvant inflammation and regulatory function of nerve growth factor. Regul Pept. 1993;46:150-4. (Pubitemid 23208301)
47. Apfel SC, Arezzo JC, Brownlee M, et al. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res. 1994;634:7-12. (Pubitemid 24013540)
48. Ramer MS, French GD, Bisby MA. Wallerian degeneration is required for both neuropathic pain and sympathetic sprouting into the DRG. Pain. 1997;72:71-8. (Pubitemid 27321903)
49. McMahon SB, Priestley JV. Peripheral neuropathies and neurotrophic factors: animal models and clinical perspectives. Curr Opin Neurobiol. 1995;5:616-24.
50. Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. Jama. 2000;284:2215-21.
51. Petty BG, Cornblath DR, Adornato BT, et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 1994;36:244-6. (Pubitemid 24239246)
52. Schifitto G, Yiannoutsos C, Simpson DM, et al. Long-term treatment with recombinant nerve growth factor for HIVassociated sensory neuropathy. Neurology. 2001;57:1313-6. (Pubitemid 32947396)
53. Svensson P, Cairns BE, Wang K, et al. Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain. 2003;104:241-7. (Pubitemid 36835893)
54. Owolabi JB, Rizkalla G, Tehim A, et al. Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat. J Pharmacol Exp Ther. 1999;289:1271-6. (Pubitemid 29246654)
55. McMahon SB, Bennett DL, Priestley JV, et al. The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule. Nat Med. 1995;1:774-80.
56. Zahn PK, Subieta A, Park SS, et al. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J Pain. 2004;5:157-63. (Pubitemid 38879394)
57. Sevcik MA, Ghilardi JR, Peters CM, et al. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain. 2005;115:128-41.
58. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther. 2010;12:94-106.
59. Lane NE, Schnitzer TJ, Birbara CA, et al. Tanezumab for the Treatment of Pain from Osteoarthritis of the Knee. N Engl J Med. 2010;363:1521-31. This is a current report on multicenter clinical trials with tenazumab, describing both the remarkable pain relief obtained in patients with osteoarthritis and the discovery of accelerated joint degeneration in some patients.
60. Zorbas M, Hurst S, Shelton D, et al. A multiple-dose toxicity study of tanezumab in cynomolgus monkeys. Regul Toxicol Pharmacol. 2010.